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Background: Protein Kinase C (PKC) dysfunction is implicated in a variety of smooth muscle disorders including
detrusor overactivity associated with frequency and urgency of micturition. In this study, we aimed to evaluate the
modulatory effects of endogenous PKC-dependent pathways on bladder storage and emptying function.
Methods: We utilized in vivo cystometry and in vitro organ bath studies using isolated bladder muscle strips
(BMS) from rats to measure contractility, intravesical pressure, and voided volume. Both in vitro and in vivo
results were statistically analyzed using one-way repeated measures ANOVA between the groups followed by
Bonferroni’s post-test, as appropriate (Systat Software Inc., San Jose, CA).
Results: Effects of PKC activators, phorbol-12,13-dibutyrate (PDBu), and phorbol-12,13-myristate (PMA), were
concentration-dependent, with high concentrations increasing frequency of micturition, and sensitivity of
intramural nerves to electrical field stimulation (EFS), in vitro, while lower concentrations had no effect on BMS
sensitivity to EFS. The PKC inhibitors, bisindolylmaleimide1 (Bim-1), (28 nM), and Ro318220 (50 μM) triggered an
increase in the number of non-voiding contractions (NVC), and a decrease in the voided volume associated with
reduced ability to maintain contractile force upon EFS, but did not affect peak force in vitro. Both low (50 nM)
and high PDBu 1 micromolar (1uM) decreased the sensitivity of BMS to carbachol. Application of a low concentration
of PDBu inhibited spontaneous contractions, in vitro, and Bim-1-induced NVC, and restored normal voiding frequency
during urodynamic recordings in vivo.
Conclusions: In summary, the effects of low PKC stimulation include inhibition of smooth muscle contractile
responses, whereas high levels of PKC stimulation increased nerve-mediated contractions in vitro, and micturition
contractions in vivo. These results indicate that endogenous PKC signaling displays a concentration-dependent
contraction profile in the urinary bladder via both smooth muscle and nerve-mediated pathways.
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Overactive bladder (OAB) is a complex clinical syndrome
which affects approximately 17% of the US population, and
is characterized by aberrant and involuntary contractions
of the detrusor smooth muscle (DSM) [1-7]. The cause
and underlying mechanisms of OAB have not been defini-
tively elucidated, however, several hypotheses have been
tested in animal models to understand the pathophysiology
of OAB in humans. Among identified mechanisms are
neurogenic and myogenic alterations of detrusor contract-
ility, as well as changes in bladder stiffness, and ion chan-
nels associated with partial bladder outlet obstruction
(PBOO), and other pathological conditions of the urinary
bladder [3,8-15]. It was previously established that a num-
ber of DSM pathologies are linked to the changes in signal-
ing proteins including, but not limited to, protein kinase C
(PKC), Rho-associated kinase (ROK), and large conduct-
ance Ca2+-activated potassium (BK) channels [5,13,16-26].
Alterations in smooth muscle myosin isoforms from the
fast phasic isoform to a more tonic one in PBOO [27,28] is
correlated with aberrant calcium signaling [29], and higher
resting levels of myosin light chain phosphorylation (MLCP)
associated with bladder overactivity [13]. It has also been
suggested that overactive bladder associated with hyper-
trophic changes in the smooth muscle may be due to a
switch from M3 to M2 muscarinic receptor signaling which
tends to show increased sensitivity [30-32]. Additionally, local
changes in the bladder wall can affect central regulation of
bladder function [33]. For instance, social stress in rats may
induce bladder overactivity, frequency of micturition, and de-
creased voided volumes [34].
Protein kinase C dysfunction has been detected in a var-
iety of smooth muscle disorders including the vasculature
(high blood pressure) [17,35], trachea (asthma) [23,36,37],
myometrium [23], and bladder (frequency of urination)
[19]. Several studies also showed that PKC is involved in
the modulation of neuronal activity [38,39], membrane re-
ceptors [40], and ion channels [22,41,42]. These wide range
effects of PKC on the critical components of smooth
muscle function suggest that alterations in any of these
components may contribute to the pathophysiology of
smooth muscle in the urinary bladder. In this regard, it was
previously reported that down-regulation of PKC in
PBOO-induced decompensated bladders is associated
with frequency of urination, whereas in compensated
bladders immunohistochemistry detected elevated PKC
levels in the bladder tissue [19]. Pharmacologic inhib-
ition of PKC in urothelium denuded BMS from normal
rabbit bladders resulted in increased spontaneous con-
tractions whereas activation of endogenous PKC activ-
ity suppressed these contractions [22]. Effects of PKC
stimulation were concentration dependent: inhibition
of spontaneous myogenic contractions and muscle tone
was detected at low levels of endogenous PKCactivation, while increased contractile force was ob-
served at high levels of PKC activation. These data sug-
gest that regulation of the detrusor tone and bladder
contractile function within the micturition cycle may
depend, at least in part, on a stimulus-dependent recip-
rocal mechanism mediated by PKC.
Bladder dysfunction often develops during progression
of many non-urological diseases including neurodegenera-
tive disorders, spinal cord injury, and diabetes [7,43,44]. A
common theme among these conditions is that they affect
the neural pathways innervating the lower urinary tract
and usually trigger the development of neurogenic de-
trusor over activity. Damage to the central nervous system
(CNS) inhibitory pathways and sensitization of peripheral
afferents projecting to the bladder can also unmask primitive
voiding reflexes leading to bladder over activity (reviewed in
de Groat [10]). A number of previous [22,45] studies revealed
that PKC can affect both nerve and muscle mechanisms that
control bladder function [46]. Therefore, aberrant regulation
of PKC due to pathophysiological changes may adversely
affect the function of both nerves and muscle in a way that
contributes to detrusor overactivity. In the present study, we
performed pharmacological evaluation of urothelium intact
BMS function in vitro (isolated muscle strips), and in vivo
(cystometry) using PKC specific activators and inhibitors in
order to determine their effects on nerve and muscle mecha-
nisms underlying urinary bladder function. The data reveal
that PKC displays a concentration-dependent activation pro-
file in the bladder with low levels of stimulation inhibiting
contractility, while high stimulation increases EFS-induced
nerve-mediated, and micturition contractions.
Methods
Animals
Sprague-Dawley male rats (N = 32, 200-250 g, Charles River
Laboratories, Malvern, PA) were utilized in this study. All
protocols were approved by the University of Pennsylvania
Institutional Animal Care and Use Committee. Rats sched-
uled to undergo in vivo cystometry were ordered pre-
catheterized (urinary bladder) from the vendor and delivered
three days post-surgery. The animals were kept in individual
cages to avoid damage to the catheters by their cage mates.
The animals were given 3 to 5 days after arrival for proper
acclimation to the new environment, and relief of stress due
to surgery and transportation.
In vitro contractility studies
Rats were euthanized by an overdose of sodium pentobar-
bital (150 mg/kg), and the bladders were removed and
placed into Tyrode’s buffer (124.9 mM NaCl, 2.5 mM KCl,
23.8 mM NaHCO3, 0.5 mM MgCl2, 0.4 mM NaH2PO4,
1.8 mM CaCl2, and 5.5 mM dextrose). Longitudinal urothe-
lium intact BMS (~2 mm × 5 mm, 20-22 mg each, mucosa
intact), were isolated and placed in individual organ baths
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equilibrated with 95% O2/5% CO2. One end of the strip
was attached to a glass rod at the bottom of the organ
chamber (Radnoti, Monrovia, CA) while the other end
was attached to a force displacement transducer (Grass
Instruments, Warwick, RI) connected to an AD Instru-
ments power-lab computerized system (AD Instruments,
Colorado Springs, CO). After 1 hour equilibration, the
length of optimal force development (L0) was determined
by manually increasing the length of each strip by 1.5 mm
increments until maximal contractile force to electrical
field stimulation at 32 Hz (EFS, 1 ms pulse width, 80 V
pulse amplitude, 5 s stimulus duration) was achieved [22].
The bath solution was changed to fresh Tyrode’s buffer,
and the muscle strips were allowed to equilibrate for
30 minutes in order to stabilize at L0 prior to performing
the contractile studies.PDBu concentration-response curve
After initial tissue preparation as described above, increas-
ing concentrations of a PKC activator, PDBu (20-640 nM),
were applied to tissue strips to evaluate the effect of the
drug on DSM tone.Carbachol concentration-response curve
Cumulative concentration-response curves were per-
formed in the presence of both low (50 nM) and high
(1 μM) PDBu, and Bim-1 (28 nM). PDBu treated muscle
strips were first pre-incubated with the drug for 30 minutes,
while Bim-1 treated muscle strips were pre-incubated for
one hour prior to performing a concentration response
curve. Control muscle strips received no treatment. After
pre-incubation with PDBu, and Bim-1, a log-dose carba-
chol concentration-response curve was performed on all
muscle strips (0.01-100 μM). PDBu and Bim-1 solutions
were added to each bath solution reaching the appropriate
final concentration in each organ bath.
Frequency-response curve in response to EFS
After equilibration in Tyrode’s buffer as described above,
individual muscle strips underwent an EFS protocol with
ascending frequency of applied electric stimuli ranging
from 0.5 to 32 Hz. Control muscle strips received no
pharmacological treatment prior to stimulation. To evalu-
ate the effects of PKC on detrusor contractility, strips were
first incubated with either Ro318220, (4.5 μM-121.5 μM,
PKC inhibitor, 1 h), bisindolylmaleimide-1 (Bim-1, PKC
inhibitor, 4 nM-32 nM, 1 h), PMA (12.5 μM–100 μM,
PKC activator, 30 min), or with phorbol-12,13-dibutyrate
(PDBu, PKC activator, 10 nM-1 μM, 30 min), before run-
ning an EFS protocol. Stimulus-response curves were cal-
culated in grams of tension per individual muscle strip.Cystometry studies
For urodynamic assessment of bladder function, conscious
rats were placed in cystometry cages (24 cm length, 16 cm
width, and 12 cm height) without restraint and allowed to
acclimate for 30 min. The tip of the exteriorized bladder
catheter located at the base of the rat neck, was connected
to a pressure transducer and the infusion pump of the
cystometry station (Small Animal Laboratory Cystometry,
Catamount Research and Development, St. Albans, VT)
using a T-shaped valve. Room temperature saline solution
(0.9% NaCl) was infused into the bladder at a rate of 80 μl/
min. Voided urine was collected in a tray connected to a
force displacement transducer, which actively integrated re-
sults into the data acquisition system. Each animal was ob-
served for approximately six to eight voiding cycles. For
animals receiving Bim-1 (28 nM), and PDBu (50 nM-
1 μM), PMA (50 μM), Ro318220 (50 μM), the concen-
trated drugs were initially diluted by saline to achieve the
final concentrations, and then were infused in the urinary
bladder in the same fashion as for control experiments.
Urodynamic values were continuously recorded using data
acquisition software (Small Animal Laboratory Cystometry,
Catamount Research and Development). The following
cystometric parameters were recorded and analysed in this
study: bladder capacity, pressure at the start of micturition,
micturition rate, continuous intra-vesical pressure, inter-
micturition interval, and the number of non-micturition
contractions. Non-micturition contractions were defined
as increased values of detrusor pressure from the baseline
that had amplitudes of at least a third of maximal pressure
from the start of micturition.Statistical analysis
All data are expressed as the mean ± SEM. N reflects the
number of animals and n is the number of strips/record-
ings. Contractility of DSM in organ bath studies was
measured and analyzed using a computerized system for
data acquisition and analysis (AD Instruments, Colorado
Springs, CO). The peak force (PF,g) and integral force (IF,
g/s) were calculated as following: the peak force (PF, g) is
the maximal amplitude of contraction in response to re-
spective stimulation measured from the baseline; and the
integral force (IF, g/s) is the area under the time-force curve
of a single contraction. Cystometric parameters were
uploaded from the acquisition software into analysis soft-
ware (SOF-552 Cystometry Data Analysis, Version 1.4,
Catamount Research and Development Inc., St. Albans,
Vermont). Maximum pressure at micturition, bladder cap-
acity, micturition volume, number of non-micturition con-
tractions, inter micturition interval, and micturition rate
indices were calculated. Both in vitro and in vivo results
were statistically analysed using one-way repeated measures
ANOVA between the groups followed by Bonferroni’s post-
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ferences between the groups were considered statistically
significant at p ≤ 0.05.
Results
PKC activation reduces contractile force and BMS
spontaneous activity at low concentrations and increases
contractility force at higher concentrations
The biphasic effects of PKC activation by PDBu on
urothelium intact isolated bladder strips in response to
increasing concentrations of the drug is displayed in
Figure 1. This phenomenon has been previously re-
ported in urothelium denuded BSM strips isolated from
the rabbit urinary bladder, and confirmed that the
urothelium did not play a role in PKC-induced inhib-
ition of bladder contractions [22]. Present data reveal
that at low levels of PKC activation (20 nM), PDBu
inhibited spontaneous contractions, and lowered the
basal smooth muscle tone from 0.2 ± 0.014 g to 0.15 ±
0.011 g tension, a 25% decrease (Figure 1 B, N = 5, n = 7,
p ≤ 0.05 to baseline). Further exposure to PDBu up to aFigure 1 Concentration dependent effects of PKC stimulation by PDBu on
contractile activity of DSM strips upon increasing concentrations of PDBu (
spontaneous contractions, and caused a small but significant decrease in t
decline and increased the muscle force above the initial basal levels. B, Sum
significantly reduced PF generation (peak force, PF) at lower PDBu concentmaximal concentration of 640 nM led to a reversal of
the initial reaction and an increased muscle tone up to
0.25 ± 0.017 g of tension, a 25% increase above the ini-
tial basal level (N = 5, n = 7, p ≤ 0.05 to baseline).
High level of PKC activation by PDBu enhances the
maximal contractile force of BMS to EFS-induced nerve
stimulation
Our preliminary studies indicated that PKC activation
by PDBu had a concentration-dependent effect on EFS-
induced nerve stimulation in isolated BMS. High (1 μM)
concentration of PDBu amplified both the peak force
(PF) response, and integral force (IF) of the bladder
strips at low levels of EFS (0-4 Hz). We, therefore,
followed the changes in BMS contractility at different
concentrations of PDBu to determine the threshold for
EFS-induced sensitivity in BMS. Our results (Figure 2)
indicate that at a concentration of 100 nM and above,
PDBu induced a significant increase in both PF, and IF
in BMS from 0.5 to 4 Hz of EFS. At 4 Hz of EFS, the PF
response in the presence of 100 nM PDBu was alreadyspontaneous contractions of isolated detrusor strips. A, Spontaneous
0–640 nM). At the initial concentration of 20 nM, PDBu inhibited
he baseline BSM tone. Continued application of PDBu reversed this
marized maximal amplitude of contractions indicates that PDBu
rations (20-40 nM; N = 5, n = 7 in each group, p < 0.05 to baseline).
Figure 2 Effects of PDBu, a PKC activator, on contractility responses of BSM to EFS in vitro. Muscle strips were pre-incubated for 30 minutes with
different concentrations of PDBu (0.01-1 μM), followed by a number of increasing frequencies of EFS stimulations (0.5-32 Hz). A, Representative
raw tracings for control (upper panel), and experimental (lower panels) groups treated with PDBu. B, Summarized peak amplitude of contractions
(PF, N = 5, n = 8 for each concentration; p≤ 0.05 at stimulations up to 4 Hz). C, PDBu caused a significant increase in IF at 0.5-4 Hz (N = 5,n = 8,
p≤ 0.05 to control values). The results were not significantly different at 8, 16, and 32 Hz for PF and IF.
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32 Hz), and 117 ± 13% of maximum value for IF (Figure 2
B and C, N = 5, n = 8, p ≤ 0.05 for both parameters). By
comparison to PDBu, the control bladder strip developed
only 52 ± 6% of PF at 4 Hz, and 69 ± 8% of maximum
value for IF. The greatest difference was seen at 0.5 Hz
with 100 nM PDBu treatment. These data confirm the
concentration-dependent effects of the PKC activator,
PDBu on EFS-mediated contractility of isolated BMS.
PKC activator, PMA, enhances the contractile force
response to EFS in BMS
In order to provide additional evidence for our above-
mentioned findings using PDBu, we used a similar PKC
activator, PMA, to evaluate its effect on EFS-induced
contractions. The data from this experimental set
showed that PMA had significant effects on both PF
and IF but required much higher concentrations to be
effective. Figure 3 (A and B) present summarized data
confirming that PMA (100 μM) stimulated an increase
in PF and IF up to 4 Hz of EFS in comparison with con-
trol strips not treated with PMA. Similar to PDBu re-
sults, the greatest change was observed at lowerfrequencies (0.5-2Hz), where the PF increased by 228 ±
20.9%, 228 ± 21.5%, and 168 ± 16.2% (Figure 3 A), and
the IF increased by 561 ± 52.3%, 219 ± 21.9%, and 196 ±
20.2%, respectively (Figure 3 B, N = 4, n = 6 in each
group, p ≤ 0.05 to control values). Starting from 25 μM
of PMA, and at 8-32 Hz of EFS stimulation, the drug
caused an average increase in IF of 82 ± 7.9%, 48 ± 5.4%,
and 80 ± 9.3% for 8, 16, and 32 Hz of EFS, respectively
(Figure 3 B, N = 4, n = 6 in each group, p ≤ 0.05 to con-
trol values).
Inhibition of PKC with Bim-1 reduces the ability of BMS to
maintain muscle force
Previous studies established that down-regulation of
PKC in PBOO is associated with frequency of urination
and a decreased volume of voided urine [19]. Addition-
ally, Bim-1, a specific inhibitor of PKC, did not affect
the PF at 32 Hz but reduced IF (ability to maintain
muscle force) by ~50% in isolated BMS during in vitro
studies when compared with control strips [22]. This
observation suggested that Bim-1 induced a significant
loss of smooth muscle ability to maintain force which is
a requirement for physiological bladder emptying. We,
Figure 3 Concentration-dependent effects of alternative PKC activator (PMA) on EFS-induced contractility. A, Summarized maximal amplitude
of contractions indicates that PMA (100 μM) significantly enhanced PF generation at 0.5-4 Hz (N = 4, n = 6 in each group, p ≤ 0.05 to baseline).
B, Application of PMA (25 μM and above) also increased IF of muscle strips at 8-32 Hz (N = 4, n = 6 in each group, p ≤ 0.05 to control values).
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of EFS frequencies in the presence and absence of Bim-
1, at different concentrations, to determine if this find-
ing was dependent on the frequency of stimulation
(Figure 4). Our data did not determine a significant dif-
ference between PF with and without Bim-1 over a range
of applied frequencies (0.5-32 Hz, Figure 4 A) andFigure 4 Contractile responses of the detrusor muscle strips to EFS upon
with different concentrations of Bim-1 (4-32 nM) for 60 min prior to EFS-in
tracers of control strips at tested frequencies, and the lower panels repres
0.5-32 Hz. B, Summarized integral force (IF, g/s, n = 5 for each group) of BS
reduction in IF upon 4 Hz and higher frequencies of EFS-induced contractconcentrations of Bim-1 (4 nM- 32 nM). There was no
substantial difference between IF values of strips with or
without Bim-1 treatment at lower frequencies of EFS (0.5-
2 Hz) either (Figure 4 B). However, EFS with frequencies
above 2 Hz caused a significant reduction in IF of BMS
subjected to Bim-1 (16 and 32 nM) in comparison with
control group (Figure 4 B). The IF declined significantly atapplication of PKC inhibitor, Bim-1. Muscle strips were pre-incubated
duced nerve stimulation. A, The upper panel shows the contractile
ent BSM contractility after Bim-1 treatments. EFS was carried out at
M responses to Bim-1. Incubation with Bim-1 caused a significant
ion (N = 3, n = 5, p ≤ 0.05 to control for 16-32 μM of Bim-1).
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of Bim-1. At a concentration of 16 nM Bim-1, the decline
in IF from control values was 53 ± 5.1%, 55 ± 4.9%, 52 ±
5.2%, and 52 ± 4.8% at 4, 8, 16, and 32 Hz of EFS, respect-
ively (N = 3, n = 5, p ≤ 0.05 to control group).
PKC inhibitors reversed EFS-induced sensitivity of BMS
upon high PKC stimulation, and decreased IF in bladder
strips
In order to determine if increased sensitivity to EFS by
high PDBu could be reversed by PKC inhibitors, we
tested the effects of Bim-1 on muscle strips previously
subjected to high concentration of PDBu. Figure 5 A
(upper panel) shows the EFS-frequency response for the
control strip without any treatment. Figure 5 A (lower
panel) includes the effects of PDBu (100 nM)Figure 5 Increased sensitivity of SM to EFS during high PKC stimulation is
included initial pre-incubation for 30 min with 100 nM of PDBu (bottom
Control strips received no PDBu (top panel). 20 minutes after the frequen
PDBu treated muscle strips. The frequency response curve was then repe
peak force shows that addition of Bim-1 to PDBu-treated strips caused a
0.5-4 Hz of EFS (N = 5, n = 7 in each group, p ≤ 0.05 to PDBu treatment at
PDBu, nor reversal by Bim-1, at 8, 16 and 32 Hz of stimulation. C, Ro3182
force of BSM contractions at both low (4.5-13.5 μM) and high (40.5-121.5
group, p ≤ 0.05 at 16 and 32 Hz to baseline).stimulation on EFS-dependent contractile responses
alone, and after incubation with Bim-1 in the presence
of PDBu. At the lowest frequency of EFS (0.5 Hz), PDBu
increased the PF by 8-fold (N = 5, n = 6, p ≤ 0.05 to con-
trol); this effect was blocked by application of Bim-1
(Figure 5 B). At 0.5-4 Hz of EFS, the PF of PDBu-
enhanced responses was reversed by addition of Bim-1,
and the PF values were similar to the control group (Fig-
ure 5 B). PDBu had no significant effect on enhancement
of PF at 8, 16 and 32 Hz of EFS, paralleling the absence
of effect to Bim-1 stimulation at the same frequencies.
In order to provide further support for the effects of
PKC inhibition on BMS contractility, we tested another
PKC inhibitor, Ro318220 (Figure 5 C). Experiments with
Ro318220 established that the drug significantly reduced
IF of muscle strips, but required much higherreversed by pre-incubation with Bim-1. A, Experimental design
panel) followed by frequency response curve to EFS (0.5-32 Hz).
cy response curve, Bim-1 (100 nM) was added for 45 minutes to the
ated for both control and drug treated DSM strips. B, Analysis of the
substantial reduction in PF which was similar with baseline levels at
respective frequencies). There was no significant enhancement by
20, an alternative PKC inhibitor, significantly reduced the integral
μM) concentrations upon 16 and 32 Hz of EFS (N = 4, n = 6 in each
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Between 0.5 and 8 Hz of applied EFS, there was no sig-
nificant difference in the level of IF at any concentration
of Ro318220 (4.5-121.5 μM). However, at 16 and 32 Hz
of EFS, Ro318220 caused a significant decrease in IF of
the strips with the greatest effect observed at 40.5 μM
and 121.5 μM (N= 5, n = 7, p ≤ 0.05 to control). At 40.5
and 121.5 μM, Ro318220 (at 16 Hz of EFS) decreased IF of
BMS to 60 ± 7.2% and 58 ± 5.4% of control values (Figure 5
C, N = 4, n = 6, p ≤ 0.05).Effects of extracellular calcium on the contractile
responses of isolated BMS
Previous studies established that endogenous PKC activity
is regulated by Ca2+-dependent and independent mecha-
nisms [35,40,45,47]. Therefore, we recorded the contractile
responses of BMS to EFS and PDBu in solutions with nor-
mal (1.8 mM) and very low (0.018 mM) calcium (Figure 6).
A reduction in calcium concentration by 100-fold led to an
85% decrease in the response to EFS (32 Hz, Figure 6 A),
and also caused a 50% decrease in the response to high
concentration of PDBu (1.0 μM, Figure 6 B).Effects of a high concentration of PDBu on BMS
frequency-contractility response upon EFS
Our prior data (Figure 2) confirmed an increased sensi-
tivity to EFS upon high level of stimulation of PKC activ-
ity, however, low levels of PKC activation had no
significant effect on BMS response to EFS stimulation.
In order to determine the stimulation frequency that
produced half-maximal response (EFS50), we obtained a
logarithmic frequency-response curve (0.1–100 Hz) inFigure 6 Effects of calcium concentration on EFS- and PDBu-induced force g
EFS (32 Hz) and PDBu (1.0 μM) in the presence of normal (1.8 mM, top trace)
of the calcium concentration by 100-fold resulted in a significant decrease inthe presence of high PDBu. EFS50 values were deter-
mined for each strip using a sigmoidal curve fit of the
data (SigmaPlot 11 Software, Systat Software Inc, San
Jose, CA). Figure 7 A (upper panel) shows the contract-
ile response of control strips whereas the lower panel
presents the raw traces of BMS subjected to PDBu appli-
cation (1 μM). Figure 7 B presents the summary data of
contractile responses of BMS treated with and without
PDBu. Application of PKC activator caused a significant
leftward shift of dose response curve with EFS50 value of
2.14 ± 0.14 Hz in comparison with control value of 10.3 ±
1.2 Hz (Figure 7 B). This is indicative of a 5-fold increase
in sensitivity of BMS strips to EFS incubated with a PKC
activator (N = 5, n = 6, p ≤ 0.05 to control group).Application of a PKC activator decreases BMS sensitivity
to carbachol
It was previously shown that PDBu can inhibit spontan-
eous myogenic contractions in vitro at low levels of PKC
activation. Our cystometric experiments also confirmed
that the PKC inhibitors, Bim-1 and Ro318220, can in-
duce frequency and NVC, and that PDBu can reverse
Bim-1-induced frequency (please see below). We,
therefore, tested the effects of different concentrations
of PDBu on cholinergic sensitivity in DSM. As seen in
Figure 8A, PDBu at 50 nM and 1 μM caused a signifi-
cant rightward shift in the carbachol concentration re-
sponse curve when compared to control group
(Figure 8 B, N = 4 and n = 6 in each group, p ≤ 0.05).
The EC50 values were 0.56 ± 0.049 nM, 4.2 ± 0.35 nM,
and 4.7 ± 0.47 nM for control, PDBu (50 nM), and
PDBu (1 μM) groups, respectively. This represented an
approximate 8-fold decrease in sensitivity of BMS toeneration in isolated BSM strips. A, Isolated DSM strips were subjected to
and very low (0.018 mM, bottom trace) Ca2+ concentration. B, Reduction
the contractile response of BSM strips to both EFS and PDBu.
Figure 7 High level of PKC activation increases sensitivity of BSM strips to low frequency of EFS. A, Upper panel shows the response of the control strip
to increasing frequencies of EFS whereas the lower panel represents the frequency-response curve after incubation with PDBu (1 μM). B, PDBu caused a
significant leftward shift (open circles) in BSM sensitivity to EFS representative of a 5-fold increase in muscle responsiveness to EFS in the presence of high
PDBu concentration (N = 5,n = 6, p≤ 0.05).
Figure 8 Both low and high PKC stimulation reduces sensitivity of BSM strips to stimulation of muscarinic receptors by carbachol. A, Raw tracers of
contractile responses to increasing concentrations of carbachol in the control (top panel) isolated BSM strip, and strips treated with low (middle panel,
50 nM) and high (bottom panel, 1 μM) concentration of PDBu. B, Both low and high PDBu caused a significant rightward shift (reduced sensitivity) in
the carbachol concentration response curve. The EC50 values were 0.56 ± 0.049, 4.2 ± 0.35, and 4.7 ± 0.47 nM for control (black circles), PDBu (50 nM,
open circles, N = 4, n = 6, p≤ 0.05 to control), and PDBu (1 micromolar (1uM), grey circles p≤ 0.05 to control)), respectively. C, Despite the reduced
sensitivity of BSM strips to carbachol stimulation after PDBu treatment, there was no significant difference in the PF of contractions between the
groups. The PF values were 2.2 ± 0.25, 2.1 ± 0.24, and 2.0 ± 0.18 g for control, PDBu (50 nM), and PDBu (100 nM) groups, respectively.
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on the maximum force produced with or without
PDBu application.Bim-1 does not affect carbachol concentration-response
curve
Figure 9 A shows the representative raw data for control
(upper trace), and Bim-1-treated (lower trace) muscle
strips upon stimulation of muscarinic receptors with car-
bachol. The summary data in Figure 9 B reveal that
Bim-1 had no significant effect on sensitivity to carba-
chol stimulation, nor on the PF generation in compari-
son with control (EC50 = 0.52 ± 0.06 μM for control
group (N = 4, n = 7) vs EC50 = 0.54 ± 0.06 μM for Bim-1
group (N = 5, n = 8, p ≤ 0.05 to control).Effects of PKC activation by PMA on urinary bladder
function in vivo evaluated by cystometry
In addition to in vitro studies, we carried out similar
experiments utilizing in vivo urodynamic approach in
awake rats. We tested the effects of PMA, a PKC acti-
vator, on bladder function. Intravesical instillation of
PMA (50 μM) caused a significant increase in fre-
quency of micturition contractions, and decline in the
voided volumes when compared to the control.
Figure 10 A shows the representative cystometric
traces from control group with a mean of 4 ± 0.5 voids
in 2 hours (Figure 10 D). The voided volume recorded
in control rats was 2.75 ± 0.23 ml, and decreased to
0.75 ± 0.43 ml with PMA (Figure 10 B and C, N = 4,
p ≤ 0.05 to control). PMA also caused a significant in-
crease in the voiding frequency to 8 ± 0.9 voids over
the same time course (Figure 10 D).Figure 9 Effects of PKC inhibition by Bim-1 on carbachol dose-response curv
carbachol in the control (top panel) strips, and strips pre-treated with Bim-1 (b
sensitivity to muscarinic stimulation (EC 50), or the maximum contraction (PF)
of carbachol).Effects of PKC activation by PDBu on urinary bladder
function in vivo evaluated by cystometry
In order to determine if low PDBu affected micturition
contractions, we tested the effects of intravesical instilla-
tion of low (50 nM) and high (1 μM) concentrations of
PDBu in in vivo studies. Figure 11 shows the cystometric
recordings upon intravesical instillation of low (A, 50 nM)
and high (B, 1 μM) concentrations of PDBu on urody-
namic parameters of rat urinary bladder. The data revealed
that low concentration of PDBu had no significant effect
on frequency of micturition (Figure 11D), nor affected the
voided volume (Figure 11C), and was similar to control
(Figure 10). However, high concentration of PDBu caused
a significant increase in the frequency of micturition con-
tractions (Figure 11B and D) along with a commensurate
decrease in the volume of voided urine from 2.7 ± 0.4 ml
to 0.3 ± 0.048 ml per cycle (Figure 11C, p ≤ 0.05).
Intravesical instillation of Ro318220 decreases the
micturition volume and increases the number of
non-voiding contractions during cystometry
Urodynamic evaluation of bladder function was performed
in the presence of a second PKC inhibitor, Ro318220.
Figure 12 shows cystometry traces recorded in control rat
without Ro318220 treatment (A) and after intravesical in-
stillation of the drug (B). The data revealed that Ro318220
application caused a 3-fold decrease in voided volume
(Figure 12 C), and an increase in NVC from 2 ± 0.5 to 6 ±
1.1 (Figure 12 D, N = 4, p ≤ 0.05 to control).
In vivo treatment with Bim-1 decreases the micturition
volume and increases the number of non-voiding contractions
during cystometry
This set of experiments was designed to determine whether
or not Bim-1, a PKC inhibitor, promotes NVC in thee. A, Raw tracers of contractile responses to increasing concentrations of
ottom panel). B, Bim-1 (28 nM) had no significant effect on either the
upon carbachol application (p = 0.061 for all concentrations
Figure 10 Cystometric evaluation of bladder function upon intravesical instillation of a PKC activator, PMA. A, Representative traces of intravesical
pressure (top panel) and voided volume (lower panel) in rats instilled with normal saline. B, Representative traces of intravesical pressure (top panel)
and voided volume (lower panel) in rats instilled with high concentration of PMA (50 μM). The rate of infusion was 80 μl/min. C, Perfusion of the
urinary bladder in vivo with high PMA induced a significant increase in the frequency of micturition contractions, and a simultaneous decrease in the
voided volume. D, Intravesical instillation of PMA also increased voiding frequency from 4 ± 0.5 to 8 ± 0.9 voids over the 2 h period (N = 4 in each
group, p≤ 0.05 to control).
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recorded in awake rats reflect the changes in urodynamic
parameters during intravesical instillation of either saline
(Figure 13 A) or Bim-1 (Figure 13 B). The upper panels of
the figures represent the intravesical pressure, whereas the
lower panels show the volumes of voided urine. Intravesical
instillation of Bim-1 (28 nM) decreased the voided volume
of urine by 56 ± 4.8% (Figure 13 C, N = 4, p ≤ 0.05), and
increased the number of non-voiding contractions by 3.5-
fold (Figure 13 D, N = 4, p ≤ 0.05 to control). An increase in
the number of NVC was consistent with the increased
spontaneous activity seen in isolated muscle strips in re-
sponse to Bim-1 application [22]. The reduced emptying,
on the other hand, may be due to the inhibitory effect of
Bim-1 on the IF or force maintenance in DSM as demon-
strated in Figure 4, and as previously established in the
rabbit bladder [22] .
Application of a low concentration of PDBu after
intravesical application of Bim-1 rescues bladder function
In order to determine whether the effects of Bim-1 on
bladder function can be reversed by subsequent application
of the PKC activator, PDBu (50 nM) was infused following
intravesical instillation of Bim-1 (Figure 14 A). The ob-
tained results showed that a low concentration of PDBu
inhibited Bim-1-induced non-voiding contractions in theurinary bladder, restored the duration of the micturition
cycle, and increased the voided volume to control levels
(Figure 14 C) when compared with the effects of Bim-1
(shown at the beginning of the tracing in Figure 14 A).
Additional studies (Figure 14 B, and D) confirmed that
these findings were not simply due to a washout effect of
the Bim-1 during infusion of PDBu. In these experiments,
we maintained the concentration of Bim-1 as in Figure 14
A, but had to increase the concentration of PDBu to 100
nM in order to see the same effect as in Figure 14 A. Since
Bim-1 is a competitive inhibitor of PDBu, the higher con-
centration of PDBu was most likely able to overcome the
effects of the initial Bim-1 infusion thus restoring a nor-
mal micturition cycle. These results confirm our in vitro
findings and suggest that PKC down-regulation, e.g. as re-
ported in PBOO [19], may contribute to frequency of mic-
turition under pathophysiological conditions.
Discussion
Physiological function of the urinary bladder is predi-
cated on an increase in urine volume during the storage
phase occurring at low intravesical pressure, and peri-
odic elimination mediated by a rapid, phasic contraction
that is maintained long enough to ensure complete blad-
der emptying [48-50]. These events are modulated by
































































































PDBu (50 nM)     PDBu  (1 µM)
Figure 11 Urodynamic recordings from non-anesthetized rats upon intravesical instillation of low and high PDBu. A, Representative traces of
intravesical pressure (top panel) and voided volume (lower panel) in rats instilled with low concentration of PDBu (50 nM). B, Representative
traces of intravesical pressure (top panel) and voided volume (lower panel) in rats instilled with high concentration of PDBu (1 μM). C, Perfusion
of the urinary bladder in vivo with low PDBu did not affect the voided volume (C) nor the number of voids (D). However, high concentration of
PDBu caused a significant increase in the frequency of micturition contractions (B; upper panel), and a decrease in voided volume (B; lower panel)
in unanesthetized rats.
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scending inhibitory inputs from the brain contribute to a
relatively quiescent, and stable bladder smooth muscle
(BSM) pressure during the storage phase, free of spon-
taneous and NVC that could increase BSM tone prema-
turely, raise intravesical pressure, and consequently reduce
bladder storage capacity leading to voiding frequency. The
mechanism by which this quiescent state is maintained
and regulated during the micturition cycle, and the contri-
bution of local mediators within the bladder wall, have not
been adequately explored, and is not well understood.
A number of previous studies using animal and human
bladders established that disruption of the quiescent state
of the BSM leads to detrusor overactivity, and increased
frequency of micturition [5,19,22,51]. It was also estab-
lished that endogenous PKC displayed a stimulus- and
concentration-dependent activation profile by inhibiting
spontaneous myogenic contractions and BSM tone at low
levels of activation, however, increasing BSM force at
higher levels of activation [22]. Overall, these studies, alongwith current results, provide insights into how bladder
pressure, voiding reflexes, and detrusor contractility are
modulated by PKC during the micturition cycle.
In the present study, we provided direct evidence that
PKC activation by high PDBu increases the sensitivity, and
enhances the contractile responses of urothelium intact
BSM strips to EFS in vitro. It was also reported that an-
other PKC activator, PMA, can enhance the maximum re-
sponse to EFS in urothelium denuded muscle strips of the
guinea pig, in vitro [20]. These results are in line with pre-
vious reports which confirmed that phorbol esters can
enhance the contractile response to EFS [20,52,53], how-
ever, these groups did not determine the sensitivity, and
concentration-dependent relationship. High levels of PKC
activation by PDBu increased the contractile responses of
bladder strips to EFS by shifting the frequency response
curve to the left (Figures 2 and 7), and increased the dur-
ation of muscle force maintenance which is essential for
bladder emptying. In vivo cystometry studies established
that enhanced PKC activation, by both PDBu and PMA,
Figure 12 Urodynamic recordings showing the effect of PMA inhibitor, Ro318220, after intravesical instillation in vivo. A, Representative traces of
intravesical pressure (top panel) and voided volume (lower panel) in a control rat instilled with saline. B, Representative traces of intravesical pressure
(top panel) and voided volume (lower panel) in a rat instilled with Ro318220 (50 μM). C, Changes in voided volume after instillation with Ro318220. D,
Number of non-voiding contractions after intravesical application of Ro318220 was increased from 2 ± 0.5 to 6 ± 1.1 over 1 h period. The decrease in
voided volume was followed by a two-fold increase in frequency over the same time period (N = 4, p≤ 0.05 to control group).
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turition contractions, and decreased the voided volume
(Figures 10 and 11). The ability of high levels of PKC
stimulation to increase voiding frequency suggests that ac-
tivation of endogenous PKC signaling may play a role in
the relay of information from the filling urinary bladder to
the CNS. For instance, several studies previously deter-
mined that PKC may participate in sensory mechanotrans-
duction [38,54]. An increase in micturition frequency may
be also due to a direct contractile effect of high concentra-
tion of PKC activator on the DSM, or the urothelium,
both of which have been shown to express PKC, thereby,
increasing intravesical pressure above the threshold re-
quired to initiate a micturition contraction. This is also in
compliance with the fact that enhanced PKC activation by
PDBu triggers an increase in BSM tone [19,22]. However,
it is not known if PDBu can cross the mucosal barrier and
penetrate into the muscle layer to cause a contraction of
the BSM, or whether it affects the release of some intrinsic
factors from the urothelium leading to contraction.Our data also revealed opposing actions of high PDBu
on EFS-induced frequency response vs carbachol-induced
concentration responses in isolated BMS. High PDBu in-
duced increased sensitivity of responses to EFS as previ-
ously mentioned. Prior studies have also shown that
activation of PKC with phorbol esters can increase the re-
lease of neurotransmitters from nerve terminals in in vitro
[46,54]. Both low (50 nM), and high PDBu (1 μM), on the
other hand, decreased sensitivity to carbachol stimulation
without effects on the PF. This data suggests that in the
absence of direct nerve stimulation by EFS, PKC activa-
tion by PDBu may have a desensitizing effect on choliner-
gic sensitivity when the nerves are bypassed, and
receptors are directly stimulated, as reported previously
for muscarinic receptors [48]. We surmise that the ability
of high, and low PKC stimulation to modulate cholinergic
sensitivity may be relevant during the mid and later stages
of the of the micturition cycle, since cholinergic activity is
known to increase as the bladder expands [55,56]. Thus,
PKC may play a role in insuring that the cholinergic
Figure 13 Inhibition of PKC activity by Bim-1 enhanced the number of non-voiding contractions recorded in vivo. A, Representative traces of intravesical
pressure (top panel) and voided volume (lower panel) in a control rat instilled with saline. B, Representative traces of intravesical pressure (top panel) and
voided volume (lower panel) in a rat instilled with intravesical Bim-1 (28 nM). Arrows point to non-voiding contractions. C, Changes in voided volume
after pre-treatment with Bim-1. D, Number of non-voiding contractions after intravesical application of PKC inhibitor. Bim-1 decreased the voided volume
by 56%, and increased the number of NVC 3.5-fold (p < 0.05, N = 4).
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ture, increasing BSM tone, and restricting bladder storage
capacity. This conclusion is supported by the fact that
both PKC inhibitors, Bim-1 and Ro318220, induced an in-
crease in NVC, decreased voided volumes, and increased
frequency of urination during in vivo cystometry. The fact
that inhibition of endogenous, or resting levels PKC activ-
ity by Bim-1 did not affect carbachol sensitivity in isolated
muscle strips (Figure 9) may indicate that carbachol sensi-
tivity is mediated by a stimulated increase of baseline PKC
activity as the bladder expands. Similar results regarding
the effects of Bim-1, on carbachol sensitivity, were ob-
tained by Schneider et al. in the human detrusor in re-
sponse to carbachol stimulation [57].
Endogenous PKC activity may play a role in maintain-
ing the quiescent state of the bladder during storage by
modulating the amplitude of spontaneous contractions
in the detrusor [22]. This study demonstrated that low
PKC stimulation by PDBu inhibited spontaneousmyogenic contractions in vitro. Additional data provided
evidence that down-regulation of PKC in PBOO model
was associated with increased frequency of urination,
and a higher amplitude of spontaneous contractions
[19]. In the current experiments, we infused the PKC in-
hibitor, Bim-1, intravesically during continuous cystome-
try. Similar to the results obtained in vitro, this
intervention resulted in a significant increase in the num-
ber of NVC, which is the in vivo correlate of spontaneous
contractions recorded in vitro. Furthermore, low PKC ac-
tivity induced by PDBu was able to competitively
antagonize and suppress Bim-1-induced NVC, and restore
normal frequency of micturition (Figure 14). The ability to
translate in vitro muscle strip studies into in vivo (cysto-
metry) indicates that PKC or similar molecules may have
significant potential therapeutic value in the treatment of
overactive bladder syndrome.
Presented data suggest that PKC modulates a wide
range of integrative effects on urinary bladder function,
Figure 14 Intravesical PKC activation restores urodynamic parameters when applied after treatment with PKC inhibitor, Bim-1. A, Changes in intravesical
pressure (top panel) and volume of voided urine (bottom panel) during bladder perfusion with Bim-1 (28 nM) followed by instillation of 50 nM of PDBu.
Low concentration of PDBu reversed the effects of Bim-1 by suppressing non-voiding contractions and increasing the voided volume to control levels. B,
In order to determine whether or not the recovery to control levels was due to a washout effect of the Bim-1 during PDBu instillation, we repeated these
experiments maintaining the concentration of Bim-1 but increasing the PDBu concentration to 100 nM. The results confirmed the previous
findings demonstrating that application of PDBu after intravesical instillation of Bim-1 rescues bladder function. C, Comparison of the voided
volume changes upon Bim-1 and PDBu applications, and upon PDBu application in the presence of Bim-1 (D).
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mechanisms, affecting both bladder muscle and innerv-
ation in the bladder wall, in a concentration-dependent
manner. One of the mechanisms associated with PKC
regulation may involve stretch-induced release of intracel-
lular calcium ([Ca 2+]) when the bladder expands during
the storage phase [58,59]. Prior studies revealed that the
bladder contains significant levels of the calcium-
dependent PKC-alpha [19], and that stretch can result in
the release of calcium from intracellular stores in bladder
smooth muscle cells [58]. A low level of [Ca 2+]i during
the early storage phase would ensure low PKC activity
which was shown to maintain the quiescent state of the
urinary bladder by suppressing spontaneous and non-
voiding contractions (Figure 15). Conversely, as the blad-
der increases in volume and approaches its capacity, both
stretch, and stretch-induced calcium release may trigger
an increase in calcium-dependent PKC activity, develop-
ment of wall tension, enhanced PKC-dependent signaling,and, as a result, bladder emptying. This scenario is sup-
ported by our present results showing that low PKC
stimulation inhibits spontaneous and non-voiding con-
tractions under both in vitro and in vivo conditions, while
high PKC stimulation increased BMS force, contractile
response to EFS known to activate intrinsic nerves, and
promoted BSM force maintenance (integral force).
Overall, our data suggest that the mechanisms of PKC
action on bladder function involves complex interac-
tions between smooth muscle and bladder nerves in a
concentration dependent manner. We also confirmed
that intrinsic bladder nerves coursing in the detrusor
layer have to be stimulated in the presence of high
PDBu in order to significantly increase BSM contractil-
ity at lower frequencies of EFS (Figure 2). This is in line
with the results from the carbachol dose response curve
showing decreased sensitivity to direct stimulation of
muscarinic receptors (Figure 8). This data strongly indi-
cates that the heightened sensitivity of the BMS in
Figure 15 Schematic presentation of the potential mechanisms linking low and high PKC activity with detrusor smooth muscle tone, contractility
and relaxation during bladder storage and emptying.
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tors, but most likely due to increased release of neuro-
transmitters from nerve terminals upon EFS, as
previously reported [54].
The complexity of the PKC effect on urinary bladder
function is further demonstrated by our urodynamic
studies showing that both inhibition of PKC by Bim-1,
and activation of PKC by high concentration of PDBu
induced frequency of micturition, and decreased voided
volumes. We surmise that the underlying causes of
these two actions are quite different. It was previously
reported [22] and also confirmed in the present study,
that inhibition of PKC by Bim-1 reduced the ability of
DSM to maintain muscle force, but had no effect on
sensitivity of the BMS to either the EFS frequency re-
sponse (Figure 4) or carbachol-concentration response
curves (Figure 8). Since endogenous, or resting levels of
PKC activity are likely to be low in comparison to stim-
ulated levels, it is possible that inhibition of these low
levels of PKC did not affect EFS or carbachol sensitivity.
This is consistent with our data showing that stimu-
lated, higher levels of PKC activity affected the sensitiv-
ity to both EFS, and carbachol, causing an increased
sensitivity to EFS, and a decreased sensitivity to carba-
chol. The current literature supports both of these ac-
tions since it was shown that PDBu can increase the
release of neurotransmitters from nerve terminals, likelyincreasing sensitivity, while decreasing the response to
direct muscarinic receptor stimulation [48].
One of the limitations of this study is that these com-
plex interactions between smooth muscle and nerves in
response to phorbol esters, exist on a continuum, and
can complicate interpretation of the data, since it is not
exactly clear where the smooth muscle effects end, and
the nerve-mediated effects begin. Thus, it is possible
that there may be some areas of overlap where the ef-
fects of smooth muscle vs neural effects have not been
adequately characterized. However, since overactive
bladder is a major concern of patients in clinical ur-
ology, the potential benefits of these pharmacological
probes for contributing to the amelioration of clinical
symptoms likely outweigh the negatives.
Thus, the similar outcomes of the inhibitor, and the
activator of PKC on frequency, and voided volume may
have different trigger points, and underlying causes. It is
clear, and our data shows that high PDBu, and PMA in-
creased the frequency of micturition contractions very
early in the micturition cycle, which, by definition, are
nerve-mediated. This invariably means that the void vol-
ume will be decreased as we have shown. The inhibitors
of PKC, Bim-1 and ro318220, also resulted in a reduced
void volume, while the number of micturition contrac-
tions stayed fairly constant over the same time course.
This implies that the inhibitors per se did not increase
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did reduce the void volume later in the micturition
cycle compared to high PDBu and PMA. The activators
demonstrated a fairly quick, and affirmative effect on
voiding early in the micturition cycle, while the effect of
the inhibitors was more progressive and delayed, sug-
gesting that the later effects are rather secondary with
slower kinetics. Thus, though not conclusive, it is more
likely that the quick response to high PDBu and PMA
early in the micturition cycle during cystometry, is me-
diated by effects on nerves, while the much slower re-
sponse to the inhibitors is mediated by either effects on
the urothelium or smooth muscle. In this regard, we
have shown that both inhibitors reduced the ability to
maintain muscle force, a requirement for efficient blad-
der emptying, and may be responsible for the decreased
void volumes.
It is well established that bladder function is modu-
lated by the descending input from the CNS. Our data,
along with prior studies, suggests that local regulation
by PKC may also play an important complementary
role in both the inhibitory (storage), and stimulatory
(emptying) phases of the micturition cycle. A decrease
of descending inhibitory activity from the brain (e.i.
“disinhibition”) to bladder motor neurons may lead to
detrusor overactivity [10]. Similarly, our data from this,
and prior studies suggests that a diminution of PKC activ-
ity within the bladder wall due to pharmacologic inhibition,
or pathologic changes, may also lead to detrusor overactiv-
ity. Both nerve-mediated and smooth muscle-related
mechanisms often complement each other, as it was shown
that partial denervation of the detrusor may alter the prop-
erties of the smooth muscle via the spread of electrical
signals between smooth muscle cells as established for
myogenic detrusor overactivity [3]. Thus, because of its
ability to modulate both nerve- and muscle-mediated con-
tractility of the bladder in a dose-dependent manner, PKC
could be one of the common links between the neuro-
genic and myogenic hypotheses of detrusor overactivity.
Conclusions
We have provided evidence that PKC stimulation in the
rat urinary bladder is involved in the regulation of bladder
storage and emptying in a concentration-dependent man-
ner. Our data suggest that PKC may also be involved in
the modulation of both neuronal, and non-neuronal, blad-
der contractility. We have also shown that the underlying
basis of this regulation involves the progressive and
concentration-dependent activation profile of PKC which
was shown to be comparable between in vitro and in vivo
conditions. Present data are consistent with prior findings
in vitro, and confirm a major physiological role for PKC in
the regulation of bladder storage and emptying within the
micturition cycle. Future studies are warranted to identifyprecise regulatory conditions modulating endogenous
PKC activity in the urinary bladder and associated effects
on the micturition cycle. This knowledge will provide a
foundation for the development of novel therapeutic
approaches to treat voiding dysfunction.
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